Britecyte, Inc. is a biotechnology company founded in 2020 that is focused on the development of cell and tissue regenerative medicine therapies to treat metabolic diseases and their complications. Metabolic diseases impair millions of lives, and treatment options available today do not adequately address the root cause of metabolic abnormalities, resulting in a significant unmet medical need. Britecyte’s approach is to design comprehensive cell and tissue regenerative medicine therapies using the company’s cell therapy platform technology to target multiple pathways underlying the complexity of metabolic diseases. Britecyte is focused on the development of allogeneic therapies (where a donor of therapeutic cells and a patient are two different individuals) that can be available “off-the-shelf” to avoid the current limitations associated with traditional autologous therapies (where a donor of therapeutic cells and a patient are the same individual) and other treatments that require matching between a donor and a patient. In the short time since the inception of the company, the team has already completed numerous preclinical studies to advance the company’s product pipeline and has filed patent applications for its advanced regenerative medicine technology. The leadership team is comprised of qualified executives in the cell and tissue regenerative medicine space with established track records and more than 80+ years of cumulative experience.
- Samson Tom, PhD, MBA; President & Chief Executive Office
- Alla Danilkovitch, PhD; Founder & Chief Scientific Officer
- Sherry Elchin, MS, CTBS; Chief Operating Officer
The MSCRF provided a commercialization program grant to advance the development of a stem cell therapy for nonalcoholic steatohepatitis (NASH), which is a serious liver disease that is triggered by disrupted metabolism. Britecyte is developing a first-in-class off-the-shelf allogeneic matrix therapy containing human mesenchymal stem cells (MSCs) that targets multiple pathways in NASH and is designed to restore the disrupted metabolism in a patient’s adipose tissue (fat), the upstream event leading to liver pathology in NASH. This strategy has a higher likelihood of success as compared to the other therapies (drugs and cell therapies) currently in development that target one specific molecular pathway and are focused on liver pathology, a downstream event of the disease. In addition to funding, the MSCRF has provided support and access to a network of experts and entrepreneurs. This has resulted in stronger collaboration with experts at prestigious institutions to advance innovation as the scope of the grant includes activities with the University of Maryland and the Johns Hopkins University.